Amgen keeps lead in KRAS race with pivotal lung cancer data, regulatory submissions  

Amgen’s sprint to the market with KRAS G12C inhibitor sotorasib continues with a first glimpse at data from its registrational Phase II study to treat lung cancer, and a spate of regulatory submissions in six regions.

With the new data showing a boost in response rates over Phase I and consistent durability, the program appears on track for approval, but the company — like its peers — isn’t much closer to finding biomarkers to stratify patients and predict prognosis. ...